Cited by 34Intracerebral and Subarachnoid Hemorrhage ResearchMesenchymal stem cell researchNeurosurgical Procedures and Complications

Cell therapy for cerebral hemorrhage: Five year follow-up report

Open access
Chang, Zhitian, Mao, Gengsheng, Sun, Lizhong, Ao, Qiang, Gu, Yongquan, Liu, Ying·2016·Experimental and Therapeutic Medicine

Abstract

The aim of the study was to examine treatment of cerebral hemorrhages with bone-marrow or human umbilical cord-derived mesenchymal stem cells (BMSCs or Hu-MSCs) and conventional surgical approaches, and determine and compare the effectiveness, feasibility, safety and reproducibility of each method. A retrospective analysis was performed on a cohort of cell-treated cerebral hemorrhage patients from October 1, 2007 to October 1, 2009. A total of 24 patients, all of whom received conventional surgical treatment, were classified as follows: i) The control group consisted of 8 patients who received only hematoma removal surgery, ii) the autologous group consisted of 7 patients who received additional autologous bone marrow mononuclear cell transplantation, and iii) the allograft group consisted of 9 patients who received additional umbilical cord mononuclear cell transplantation. After conventional hematoma removal surgery and X-ray supervision within 24 h and at 7 days, neurological disability and function tests were completed 3, 6, 12, 36 and 60 months later. The T-cell marker plasma levels were analyzed after 60 months. The results showed that, at approximately 3.5 months after graft the hematomas in all the groups were completely reabsorbed as observed on computed tomography scans. However, the functional outcomes in the cell-transplanted groups were better than in the control group after 5 years. While the National Institutes of Health Stroke Scale, modified Rankin score and modified Barthel index scores were simliar in the cell-transplanted groups, patients in the allograft group had better outcomes than those in the autologous graft group starting at 3 months and until the end of the follow-up period. The serum levels of T-cell markers CD4, CD56 and human leukocyte antigen-DR in the allograft group showed no signs of immunogenic graft complications and there were no significant differences in T-cell subtypes among the patient groups. The results of the present study suggest that, treatment of cerebral hemorrhage patients can be safely and effectively accomplished using Hu-MSC grafting and larger clinical trials should be considered in the future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3892/etm.2016.3811

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Intracerebral injections are clinically feasible and are performed in a variety of clinical scenarios and preclinical settings.

    “Intracerebral injections are clinically feasible, and are performed in a variety of clinical scenarios (17–23), as well as in various preclinical settings (4, 24–27).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Chang, Z., Mao, G., Sun, L., Ao, Q., Gu, Y., & Liu, Y.
Affiliations
  • China Medical University (CN)
  • Chinese People's Armed Police General Hospital (CN)
  • Capital Medical University (CN)
Corresponding author
  • Gu, Yongquan
  • Liu, Ying
Venue
Experimental and Therapeutic Medicine
Published
2016-10-18
Volume
12
Issue
6
Pages
3535-3540
ISSN
  • 1792-0981 (ISSN-L)
  • 1792-1015
OpenAlex
W2535285119
Cited by
34
References
18
Citations by year
2026: 3 · 2025: 4 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 3 · 2020: 5 · 2019: 1 · 2018: 2 · 2017: 2
FWCI
1.25
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Experimental and Therapeutic Medicine (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National High-tech Research and Development Program (2011AA020101)
  • National Institute on Alcohol Abuse and Alcoholism (R03AA020101)
Topics
  • Health Sciences › Medicine › Neurology › Intracerebral and Subarachnoid Hemorrhage Research
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Neurology › Neurosurgical Procedures and Complications
Keywords
cerebral hemorrhage, cell therapy, mesenchymal stem cells, umbilical cord-derived stem cells, bone marrow mononuclear cells, autologous transplantation, allogeneic transplantation, functional outcome, T-cell markers, immunogenicity, long-term follow-up

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review